多がんスクリーニング市場：検査タイプ別、がんタイプ別、技術別、決済元別、用途別、エンドユーザー別-2025～2030年の世界予測

多がんスクリーニング市場は、2024年には15億3,000万米ドルとなり、2025年には16億7,000万米ドル、CAGR 10.05%で成長し、2030年には27億2,000万米ドルに達すると予測されています。

近年、医療のセグメントでは、がんの早期発見と管理が大きく進化しています。ゲノミクス、診断学、臨床研究が交差する急成長セグメントである多がんスクリーニングは、臨床医によるがん発見へのアプローチ方法を変革しつつあります。この新たなパラダイムは、先端技術と統合的診断プラットフォームを活用することで、潜在的な悪性腫瘍についてより包括的な洞察を提供しようとするものです。

多がん検診の進化は、早期診断、リスク評価、個別化された治療戦略を支援する研究の増加によって推進されています。このセグメントの革新者たちは、精度を向上させ、偽陽性を減少させるために、スクリーニングプロトコルを絶えず改良しています。その結果、患者はより個別化されたタイムリーな介入から恩恵を受け、ひいては全体的な治療成績が向上します。

先駆的な研究と臨床的検証は、正確な分子プロファイリングと複数の診断検査の統合の重要性を強調しています。これらの進歩は、臨床的な意思決定を強化するだけでなく、侵襲性が低く、がんの存在を高度に予測できる診断スクリーニング法への道を開くものでもあります。早期発見の継続的な重視は、生存率の向上と医療資源の効率的な配分に貢献し、プレシジョン・メディシン（精密医療）に向けた旅の重要なマイルストーンとなります。

多がん検診を再定義する変革的シフト

このセグメントにおける最近の変革的シフトは、産業標準と市場力学を根本的に再定義しています。次世代シーケンス、質量分析、ポリメラーゼ連鎖反応などの技術的飛躍的進歩は、診断精度を新たな高みへと押し上げました。これらの進歩に加え、臨床医ががんバイオマーカーを検出・モニタリングする方法を変えつつある検査室開発検査やリキッドバイオプシー技術への依存度が高まっています。

スクリーニング技術の進化は、早期発見と予防医療への医療の優先順位の幅広いシフトと密接に関連しています。現在、少量のバイオマーカーのシナリオにおいて、迅速なターンアラウンドタイムと高感度を可能にするプラットフォームの開発が重視されています。さらに、新しい遺伝学的と分子生物学的分析の統合は、がんの不均一性をより微妙に理解することを容易にしました。その結果、より正確なリスク層別化が可能になり、これは様々ながん種とそれに対応する治療選択肢との間の複雑な相互作用を考慮する際に不可欠です。

情勢が変化し続ける中、利害関係者は、こうしたイノベーションを活用するために必要な戦略的必須事項への認識を深めています。最先端の診断ツールや包括的なスクリーニングプロトコルへの投資は、臨床診療を近代化するだけでなく、従来の反応的な戦略よりも早期介入を重視するパラダイムシフトにも寄与していることは明らかです。

多がんスクリーニング市場の主要セグメンテーション洞察

多がんスクリーニング市場を包括的に分析すると、現在の産業力学を理解する上で中心となる多面的なセグメンテーション洞察が明らかになります。検査タイプによるセグメンテーションには、遺伝子パネル、ラボ開発検査、リキッドバイオプシーの厳密な評価が含まれます。これらの診断方法は、がん検出への多様なアプローチを提供し、それぞれが早期介入戦略を支援するために独自のバイオマーカーと技術的なニュアンスを活用しています。研究開発や産業の専門家は、遺伝子パネルは素因や変異の同定に不可欠な遺伝学的ロードマップを提供し、検査室開発検査はオーダーメイドの評価と検査室定義のパラメーターを可能にし、リキッドバイオプシーは迅速な結果で侵襲性を最小化すると指摘しています。

がんタイプ別に区分すると、乳がん、結腸直腸がん、白血病、肺がん、非特異的多臓器がん、前立腺がんなどのがんを精査しています。がん種が多様であるため、それぞれの生物学的メカニズムや診断上の課題をしっかりと理解する必要があります。さらに、技術によるセグメンテーションでは、質量分析、マイクロアレイ、次世代シークエンシング、ポリメラーゼ連鎖反応などの様々なプラットフォームが発表され、それぞれがこのセグメントを精密に進歩させています。これらの技術は、バイオマーカーを定量化し、遺伝子プロファイルを理解するための異なるアプローチを提供し、治療レジメンを調整するのに役立ちます。

市場はまた、政府補助金、自己負担金、民間医療保険などの枠組みの中で診断ソリューションが評価される決済源によっても区分されます。このセグメンテーションは、市場の導入とアクセシビリティを支配する経済的・施策的影響を強調するものです。診断スクリーニングは早期発見とリスク評価、予後予測は患者モニタリング、治療選択、治療効果評価に分けられます。研究用途の領域では、バイオマーカー探索と遺伝子研究に焦点を当てたサブセグメントがあり、継続的な技術革新の触媒として機能しています。最後に、エンドユーザーによる分類には、外来手術センター、診断センター、病院、研究機関、専門クリニックが含まれ、多様な医療環境における多がんスクリーニング技術の幅広い展開が強調されています。

これらのセグメンテーション洞察は、市場の促進要因と障壁の詳細な理解を提供し、利害関係者が現在の状況を形成する様々な診断、技術、経済的要因に基づいて情報に基づいた意思決定を行うことを支援します。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん罹患率の増加と高齢化の進行
    • 医療費の増加と政府の取り組み
    • 患者の転帰改善のための早期発見の重要性が高まっている
  • 抑制要因
    • 多がんスクリーニングに関連する高コスト
  • 機会
    • 非侵襲的と低侵襲的スクリーニング手順の開発
    • ビッグデータとデジタルヘルスプラットフォームの統合
  • 課題
    • 十分な安全性と有効性に関する懸念に対処する
• 市場セグメンテーション分析
  • 検査タイプ：患者に優しいサンプル採取プロセスのため、液体生検が好まれる傾向が高まっている
  • 用途：予測における多がんスクリーニングの応用拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 多がんスクリーニング市場：検査タイプ別

• イントロダクション
• 遺伝子パネル
• 臨床開発検査
• 液体生検

第7章 多がんスクリーニング市場：がんタイプ別

• イントロダクション
• 乳がん
• 大腸がん
• 白血病
• 肺がん
• 非特異的多臓器がん
• 前立腺がん

第8章 多がんスクリーニング市場：技術別

• イントロダクション
• 質量分析
• マイクロアレイ
• 次世代シーケンス
• ポリメラーゼ連鎖反応

第9章 多がんスクリーニング市場：決済元別

• イントロダクション
• 政府補助金
• 自己負担
• 民間医療保険

第10章 多がんスクリーニング市場：用途別

• イントロダクション
• 診断スクリーニング
  • 早期発見
  • リスクアセスメント
• 予後
  • 患者モニタリング
  • 治療法の選択
  • 治療効果評価
• 研究用途
  • バイオマーカーの発見
  • 遺伝子研究

第11章 多がんスクリーニング市場：エンドユーザー別

• イントロダクション
• 外来手術センター
• 診断センター
• 病院
• 研究機関
• 専門クリニック

第12章 南北アメリカの多がんスクリーニング市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋の多がんスクリーニング市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの多がんスクリーニング市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析、2024年
• FPNVポジショニングマトリックス、2024年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• ANPAC Bio-Medical Science Co., Ltd.
• Burning Rock BIoTech Limited
• Caris Life Sciences
• Coyne Medical Ltd.
• Delfi Diagnostics, Inc.
• Elypta AB
• EpiCypher, Inc.
• Epigenomics AG
• Exact Sciences Corporation
• Foundation Medicine, Inc.
• Freenome Holdings, Inc.
• Fulgent Genetics, Inc.
• Gene Solutions
• Grail, LLC by Illumina, Inc.
• Guangzhou AnchorDx Medical Co., Ltd.
• Guardant Health, Inc.
• Invitae Corporation
• Laboratory Corporation of America Holdings
• Lucence Health Inc.
• Micronoma, Inc.
• MiRXES Pte Ltd.
• Myriad Genetics, Inc.
• Natera, Inc.
• Naveris, Inc.
• NeoGenomics Laboratories
• OneTest
• Siemens Healthineers AG
• StageZero Life Sciences. Ltd.

LIST OF FIGURES

• FIGURE 1. MULTICANCER SCREENING MARKET MULTI-CURRENCY
• FIGURE 2. MULTICANCER SCREENING MARKET MULTI-LANGUAGE
• FIGURE 3. MULTICANCER SCREENING MARKET RESEARCH PROCESS
• FIGURE 4. MULTICANCER SCREENING MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 23. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 29. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. MULTICANCER SCREENING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MULTICANCER SCREENING MARKET DYNAMICS
• TABLE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 65. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 73. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 74. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. CANADA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 76. CANADA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 77. CANADA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 78. CANADA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 79. CANADA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. CANADA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 81. CANADA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 82. CANADA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 83. CANADA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 85. MEXICO MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 86. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 88. MEXICO MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. MEXICO MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 91. MEXICO MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 93. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 94. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 95. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 96. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 97. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 99. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 103. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 105. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 110. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 113. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 114. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 115. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 116. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 117. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 119. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 120. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 121. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. CHINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 123. CHINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 124. CHINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 125. CHINA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 126. CHINA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. CHINA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 128. CHINA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 129. CHINA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 130. CHINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. INDIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 132. INDIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 133. INDIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 134. INDIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 135. INDIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. INDIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 137. INDIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 138. INDIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 139. INDIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 141. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 142. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 144. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 146. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 147. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 148. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 149. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 150. JAPAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 151. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 152. JAPAN MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 153. JAPAN MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 154. JAPAN MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 155. JAPAN MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 156. JAPAN MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 157. JAPAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 159. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 160. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 161. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 162. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 164. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 165. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 166. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 167. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 168. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 169. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 170. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 171. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 173. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 174. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 175. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 176. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 178. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 179. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 180. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 182. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 183. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 184. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 185. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 186. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 187. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 188. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 189. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 191. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 192. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 193. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 194. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 195. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 196. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 197. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 198. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 199. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 200. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 201. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 202. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 203. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 204. THAILAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 205. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 206. THAILAND MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 207. THAILAND MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 208. THAILAND MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 209. THAILAND MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 210. THAILAND MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 211. THAILAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 212. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 213. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 214. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 215. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 216. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 217. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 218. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 219. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 220. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 225. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 226. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 227. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 228. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 229. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 230. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 231. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 232. DENMARK MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 233. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 234. DENMARK MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 235. DENMARK MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 236. DENMARK MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 237. DENMARK MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 238. DENMARK MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 239. DENMARK MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 240. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 241. EGYPT MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 242. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 243. EGYPT MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 244. EGYPT MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 245. EGYPT MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 246. EGYPT MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 247. EGYPT MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 248. EGYPT MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 249. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 250. FINLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 251. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 252. FINLAND MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 253. FINLAND MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 254. FINLAND MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 255. FINLAND MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 256. FINLAND MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 257. FINLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 258. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 259. FRANCE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 260. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 261. FRANCE MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 262. FRANCE MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 263. FRANCE MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 264. FRANCE MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 265. FRANCE MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 266. FRANCE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 267. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 268. GERMANY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 269. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 270. GERMANY MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 271. GERMANY MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 272. GERMANY MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 273. GERMANY MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 274. GERMANY MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 275. GERMANY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 276. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 277. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 278. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 279. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 280. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 281. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 282. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 283. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 284. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 285. ITALY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 286. ITALY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 287. ITALY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 288. ITALY MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 289. ITALY MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 290. ITALY MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 291. ITALY MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 292. ITALY MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 293. ITALY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 294. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 295. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 296. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 297. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 298. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 299. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 300. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 301. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 302. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 303. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 304. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 305. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 306. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 307. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 308. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 309. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 310. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 311. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 312. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 313. NORWAY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 314. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 315. NORWAY MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 316. NORWAY MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 317. NORWAY MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 318. NORWAY MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 319. NORWAY MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 320. NORWAY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 321. POLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 322. POLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 323. POLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 324. POLAND MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 325. POLAND MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 326. POLAND MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 327. POLAND MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 328. POLAND MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 329. POLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 330. QATAR MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 331. QATAR MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 332. QATAR MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 333. QATAR MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
• TABLE 334. QATAR MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 335. QATAR MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
• TABLE 336. QATAR MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 337. QATAR MULTICANCER SCREENING MARKET SIZE, B

The Multicancer Screening Market was valued at USD 1.53 billion in 2024 and is projected to grow to USD 1.67 billion in 2025, with a CAGR of 10.05%, reaching USD 2.72 billion by 2030.

In recent years, the healthcare arena has witnessed a significant evolution in the early detection and management of cancers. Multicancer screening, a burgeoning field at the intersection of genomics, diagnostics, and clinical research, is transforming the way clinicians approach cancer detection. This emerging paradigm seeks to offer more comprehensive insights into potential malignancies by leveraging advanced technologies and integrative diagnostic platforms.

The evolution of multicancer screening is driven by a growing body of research that supports early diagnosis, risk assessment, and tailored treatment strategies. Innovators in the field are continuously refining screening protocols to improve accuracy and reduce false positives. As a result, patients benefit from more personalized and timely interventions, which in turn enhance overall treatment outcomes.

Pioneering studies and clinical validations have underscored the importance of precise molecular profiling and the integration of multiple diagnostic tests. These advancements not only augment clinical decision-making but also pave the way for diagnostic screening methods that are both less invasive and highly predictive of cancer presence. The continued emphasis on early detection contributes to improved survival rates and a more efficient allocation of healthcare resources, marking a critical milestone in the journey toward precision medicine.

Transformative Shifts Redefining the Multicancer Screening Landscape

Recent transformative shifts within the field have fundamentally redefined industry standards and market dynamics. Technological breakthroughs such as next-generation sequencing, mass spectrometry, and polymerase chain reaction have propelled diagnostic accuracy to new heights. These advancements are complemented by a growing reliance on laboratory developed tests and liquid biopsy techniques that are changing the way clinicians detect and monitor cancer biomarkers.

The evolution in screening technologies is closely linked with a broader shift in healthcare priorities toward early detection and preventive care. Emphasis is now placed on developing platforms that allow for rapid turnaround times and higher sensitivity in low-volume biomarker scenarios. Furthermore, integration of novel genetic and molecular analyses has facilitated a more nuanced understanding of cancer heterogeneity. This, in turn, enables more accurate risk stratification, which is vital when considering the complex interplay between various cancer types and corresponding treatment options.

As the landscape continues to adapt, stakeholders are increasingly aware of the strategic imperatives required to harness these innovations. It is clear that investments in state-of-the-art diagnostic tools and comprehensive screening protocols are not only modernizing clinical practices but are also contributing to a paradigm shift that emphasizes early intervention over conventional reactive strategies.

Key Segmentation Insights in the Multicancer Screening Market

A comprehensive analysis of the multicancer screening market reveals multifaceted segmentation insights central to understanding current industry dynamics. The segmentation based on test type includes a rigorous evaluation of gene panels, laboratory developed tests, and liquid biopsies. These diagnostic modalities offer diverse approaches to cancer detection, each leveraging unique biomarkers and technological nuances to support early intervention strategies. Researchers and industry experts note that gene panels provide a genetic roadmap that is essential for identifying predispositions and mutations, while laboratory developed tests allow for tailored assessments and laboratory-defined parameters, and liquid biopsies minimize invasiveness with rapid results.

When segmented by cancer type, the market research scrutinizes an array of cancers including breast, colorectal, leukemia, lung, non-specific multi-organ cancers, and prostate cancer. The diversity within cancer types necessitates a robust understanding of the biological mechanisms at play and the variable diagnostic challenges associated with each category. Furthermore, segmentation based on technology introduces a spectrum of platforms such as mass spectrometry, microarray, next-generation sequencing, and polymerase chain reaction, each advancing the field with precision. These technologies offer different approaches to quantifying biomarkers and understanding genetic profiles, which aids in tailoring treatment regimens.

The market is also segmented by payment source where diagnostic solutions are evaluated within frameworks that include government subsidies, out-of-pocket payments, and private health insurance. This segmentation underscores the economic and policy influences governing market adoption and accessibility. Additionally, segmentation by application brings forth insights under diagnostic screening, prognostics, and research applications, with diagnostic screening further differentiated by early detection and risk assessment, and prognostics divided into patient monitoring, therapy selection, and treatment efficacy assessment. Within the realm of research applications, sub-segmentations focus on biomarker discovery and genetic research, thereby serving as a catalyst for continuous innovation. Lastly, categorization based on the end user includes ambulatory surgical centers, diagnostic centers, hospitals, research institutions, and specialty clinics, highlighting the broad deployment of multicancer screening technologies across diverse healthcare settings.

Together, these segmentation insights provide a detailed understanding of market drivers and barriers, empowering stakeholders to make informed decisions based on varying diagnostic, technological, and economic factors that shape the current landscape.

Based on Test Type, market is studied across Gene Panel, Laboratory Developed Test, and Liquid Biopsy.

Based on Cancer Type, market is studied across Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Non-Specific Multi-Organ Cancer, and Prostate Cancer.

Based on Technology, market is studied across Mass Spectrometry, Microarray, Next - Generation Sequencing, and Polymerase Chain Reaction.

Based on Payment Source, market is studied across Government Subsidies, Out-of-Pocket Payment, and Private Health Insurance.

Based on Application, market is studied across Diagnostic Screening, Prognostics, and Research Applications. The Diagnostic Screening is further studied across Early Detection and Risk Assessment. The Prognostics is further studied across Patient Monitoring, Therapy Selection, and Treatment Efficacy Assessment. The Research Applications is further studied across Biomarker Discovery and Genetic Research.

Based on End User, market is studied across Ambulatory Surgical Centers, Diagnostic Centers, Hospitals, Research Institutions, and Specialty Clinics.

Regional Insights Shaping the Global Multicancer Screening Market

Regional dynamics play a crucial role in steering the multicancer screening market, with distinct trends emerging across various geographies. In the Americas, increased funding for research, supportive regulatory frameworks, and a strong emphasis on early detection have collectively accelerated the adoption of advanced screening technologies. An ecosystem enriched by academic collaborations and public-private partnerships is fostering the rapid integration of these diagnostics into routine clinical practice.

Across Europe, the Middle East, and Africa, the landscape is simultaneously evolving with an emphasis on harmonized healthcare practices and large-scale government interventions targeted at disease prevention. The region has seen a progressive push towards the implementation of precision screening, driven by both rising cancer incidences and increasing awareness regarding early diagnosis. Meanwhile, the Asia-Pacific region has emerged as an influential player, characterized by rapid economic growth, technological advancements, and broad patient accessibility. Investment in state-of-the-art diagnostic centers and the ongoing integration of innovative testing methodologies are establishing a robust market presence that is poised for sustainable growth.

Collectively, these regional insights emphasize the global nature of the market and highlight the varying pace at which different regions are adapting to and adopting the transformative potential of multicancer screening technologies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Driving Innovation in Multicancer Screening

The multicancer screening market is marked by the active participation of several trailblazing companies whose innovations drive the industry's momentum. Noteworthy players such as ANPAC Bio-Medical Science Co., Ltd. and Burning Rock Biotech Limited have carved out critical niches by offering advanced diagnostic tests and comprehensive genomic analyses. Organizations like Caris Life Sciences and Coyne Medical Ltd. have significantly influenced cancer diagnostics by integrating cutting-edge bioinformatics with traditional laboratory operations.

Other key industry leaders, including Delfi Diagnostics, Inc. and Elypta AB, are leveraging novel molecular profiling techniques to enhance early detection and risk assessment capabilities. EpiCypher, Inc., Epigenomics AG, and Exact Sciences Corporation have also played pivotal roles by further refining the accuracy of diagnostic platforms while expanding the scope of genetic screening. Foundation Medicine, Inc., Freenome Holdings, Inc., and Fulgent Genetics, Inc. have introduced innovative testing protocols that incorporate multi-dimensional data analysis and refined patient stratification. Companies such as Gene Solutions and Grail, LLC by Illumina, Inc. have demonstrated expertise in combining robust research with clinical applications.

Further contributions from Guangzhou AnchorDx Medical Co., Ltd., Guardant Health, Inc., Invitae Corporation, and Laboratory Corporation of America Holdings underscore an industry-wide commitment to precision and efficiency. In addition, Lucence Health Inc., Micronoma, Inc., MiRXES Pte Ltd., and Myriad Genetics, Inc. have set benchmarks for integrating streamlined diagnostics with next-generation treatment selections. The market continues to benefit from the diverse contributions of Natera, Inc., Naveris, Inc., NeoGenomics Laboratories, OneTest, Siemens Healthineers AG, and StageZero Life Sciences. Their collective expertise fosters a competitive environment that fuels ongoing advancements in early cancer screening and personalized medicine applications.

The report delves into recent significant developments in the Multicancer Screening Market, highlighting leading vendors and their innovative profiles. These include ANPAC Bio-Medical Science Co., Ltd., Burning Rock Biotech Limited, Caris Life Sciences, Coyne Medical Ltd., Delfi Diagnostics, Inc., Elypta AB, EpiCypher, Inc., Epigenomics AG, Exact Sciences Corporation, Foundation Medicine, Inc., Freenome Holdings, Inc., Fulgent Genetics, Inc., Gene Solutions, Grail, LLC by Illumina, Inc., Guangzhou AnchorDx Medical Co., Ltd., Guardant Health, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Lucence Health Inc., Micronoma, Inc., MiRXES Pte Ltd., Myriad Genetics, Inc., Natera, Inc., Naveris, Inc., NeoGenomics Laboratories, OneTest, Siemens Healthineers AG, and StageZero Life Sciences. Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to drive further innovation by investing in research and development that spans the full spectrum of diagnostic modalities. It is advisable to enhance collaborations between clinical research institutions and diagnostic companies to accelerate the translation of novel biomarkers into clinically actionable tools. Strategic investments in technologies such as next-generation sequencing, mass spectrometry, and polymerase chain reaction will provide the robust framework required for developing more precise screening solutions.

Stakeholders should also consider leveraging real-world evidence and comprehensive market segmentation data when tailoring product offerings to the evolving needs of diverse patient populations. Engaging with regulatory bodies to streamline approval processes and actively participating in public health initiatives can foster a more supportive environment for rapid adoption and scaling of multicancer screening programs. The effective integration of digital health tools and real-time data analytics into diagnostic platforms is another pertinent recommendation that can improve patient monitoring and treatment efficacy assessments. Overall, a proactive approach backed by agile decision-making and strategic foresight is essential to stay ahead in this competitive and ever-evolving market.

Conclusion: Embracing Innovation and Precision in Cancer Screening

In summary, the multicancer screening market reflects a transformative period marked by rapid technological advancements and sophisticated segmentation models. Detailed analysis across diverse diagnostic methods, cancer types, and technological applications reveals an industry that is not only dynamic but also deeply committed to early and precise detection. The global regional insights further emphasize the necessity of customized approaches tailored to specific market dynamics, while leading company innovations set the stage for further breakthroughs. The ongoing focus on precision medicine underlines the importance of continuous research and collaborative efforts, ensuring that advancements in diagnostic tools translate into improved patient outcomes and enhanced clinical practices.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cancer disease and rising aging population
    • 5.1.1.2. Rise in healthcare expenditure and government initiative
    • 5.1.1.3. Growing emphasis on early detection for improved patient outcomes
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with multicancer screening
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of non-invasive and minimally invasive screening procedures
    • 5.1.3.2. Integration of big data and digital health platforms
  • 5.1.4. Challenges
    • 5.1.4.1. Addressing concerns associated with adequate safety and efficacy
• 5.2. Market Segmentation Analysis
  • 5.2.1. Test Type: Increasing preference for liquid biopsy due to its patient-friendly sample collection process
  • 5.2.2. Application: Expanding application of multicancer screening in prognostics
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Multicancer Screening Market, by Test Type

• 6.1. Introduction
• 6.2. Gene Panel
• 6.3. Laboratory Developed Test
• 6.4. Liquid Biopsy

7. Multicancer Screening Market, by Cancer Type

• 7.1. Introduction
• 7.2. Breast Cancer
• 7.3. Colorectal Cancer
• 7.4. Leukemia
• 7.5. Lung Cancer
• 7.6. Non-Specific Multi-Organ Cancer
• 7.7. Prostate Cancer

8. Multicancer Screening Market, by Technology

• 8.1. Introduction
• 8.2. Mass Spectrometry
• 8.3. Microarray
• 8.4. Next - Generation Sequencing
• 8.5. Polymerase Chain Reaction

9. Multicancer Screening Market, by Payment Source

• 9.1. Introduction
• 9.2. Government Subsidies
• 9.3. Out-of-Pocket Payment
• 9.4. Private Health Insurance

10. Multicancer Screening Market, by Application

• 10.1. Introduction
• 10.2. Diagnostic Screening
  • 10.2.1. Early Detection
  • 10.2.2. Risk Assessment
• 10.3. Prognostics
  • 10.3.1. Patient Monitoring
  • 10.3.2. Therapy Selection
  • 10.3.3. Treatment Efficacy Assessment
• 10.4. Research Applications
  • 10.4.1. Biomarker Discovery
  • 10.4.2. Genetic Research

11. Multicancer Screening Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
• 11.3. Diagnostic Centers
• 11.4. Hospitals
• 11.5. Research Institutions
• 11.6. Specialty Clinics

12. Americas Multicancer Screening Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Multicancer Screening Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Multicancer Screening Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Function Health partners with GRAIL to expand Galleri multi-cancer early detection test access
  • 15.3.2. Lucence and DxD Hub partner to enhance multi-cancer detection through alternative sample testing
  • 15.3.3. Freenome secures USD 254 million funding to advance multi-cancer blood tests and drive early detection innovations
  • 15.3.4. PanGIA Biotech Advances Multi-Cancer Detection with Liquid Biopsy Platform
  • 15.3.5. Introduction of Riskguard, A Hereditary Cancer Screening Test by Exact Sciences Corp
  • 15.3.6. Strategic Partnership Between SeekIn Inc. and Oncolnv to Enhance Global Cancer Detection Efforts
  • 15.3.7. Collaboration Between AnchorDx and DiaCarta to Revolutionize Global Cancer Screening
  • 15.3.8. Burning Rock Biotech Achieves Global Recognition with OverC Multi-Cancer Detection Blood Test
  • 15.3.9. Elypta Attains ISO 13485:2016 Certification, Advancing GAGome-Based Multicancer Detection
  • 15.3.10. Strategic Acquisition by Freenome Amplifies Cancer Screening Capabilities through Oncimmune Ltd's Advanced Diagnostics
  • 15.3.11. Lucence Advances Cancer Detection with Innovative MCED Blood Test: A Strategic Unveiling in the U.S.
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. ANPAC Bio-Medical Science Co., Ltd.
• 2. Burning Rock Biotech Limited
• 3. Caris Life Sciences
• 4. Coyne Medical Ltd.
• 5. Delfi Diagnostics, Inc.
• 6. Elypta AB
• 7. EpiCypher, Inc.
• 8. Epigenomics AG
• 9. Exact Sciences Corporation
• 10. Foundation Medicine, Inc.
• 11. Freenome Holdings, Inc.
• 12. Fulgent Genetics, Inc.
• 13. Gene Solutions
• 14. Grail, LLC by Illumina, Inc.
• 15. Guangzhou AnchorDx Medical Co., Ltd.
• 16. Guardant Health, Inc.
• 17. Invitae Corporation
• 18. Laboratory Corporation of America Holdings
• 19. Lucence Health Inc.
• 20. Micronoma, Inc.
• 21. MiRXES Pte Ltd.
• 22. Myriad Genetics, Inc.
• 23. Natera, Inc.
• 24. Naveris, Inc.
• 25. NeoGenomics Laboratories
• 26. OneTest
• 27. Siemens Healthineers AG
• 28. StageZero Life Sciences. Ltd.